How to Inactivate Human Ubiquitin E3 Ligases by Mutation

Abstract

E3 ubiquitin ligases are the ultimate enzymes involved in the transfer of ubiquitin to substrate proteins, a process that determines the fate of the modified protein. Numerous diseases are caused by defects in the ubiquitin-proteasome machinery, including when the activity of a given E3 ligase is hampered. Thus, inactivation of E3 ligases and the resulting effects at molecular or cellular level have been the focus of many studies during the last few years. For this purpose, site-specific mutation of key residues involved in either protein interaction, substrate recognition or ubiquitin transfer have been reported to successfully inactivate E3 ligases. Nevertheless, it is not always trivial to predict which mutation(s) will block the catalytic activity of a ligase. Here we review over 250 sitespecific inactivating mutations that have been carried out in 120 human E3 ubiquitin ligases. We foresee that the information gathered here will be helpful for the design of future experimental strategies.

The ubiquitin ligase Ariadne-1 regulates neurotransmitter release via ubiquitination of NSF

“…5 A ). The latter was generated by mutating its active site Cysteine at position 357 to a Serine (C357S), an amino acid that is able to bind ubiquitin but unable to transfer it to the substrates, as ubiquitin remains attached to the Serine through an oxyester bond ( 30 , 38 ). In order to improve the detection of ubiquitin signal, cells were further transfected with FLAG-tagged ubiquitin ( Fig.…”

A Mechanistic Insight into the Pathogenic Role of Interleukin 17A in Systemic Autoimmune Diseases

“…Other functions of Act1 include the E3 ubiquitin ligase activity towards TRAFs that may control their fate and activity in IL-17A signaling, as illustrated by the K63-linked polyubiquitination of TRAF6 mediated by TAK-1 [ 2 , 34 , 35 ]. Lysine-124 residue of TRAF6 has been implicated in Act1-mediated ubiquitination of TRAF6 and TRAF6's ability to mediate IL-17-induced activation of NFkB [ 36 ].…”

A Membrane-Tethered Ubiquitination Pathway Regulates Hedgehog Signaling and Heart Development

“…We constructed two variants of MGRN1 (MGRN1 Mut1 and MGRN1 Mut2 ) carrying mutations in highly conserved residues of the RING domain ( Figure S4B). These mutations are known to abolish binding between RING domains and their cognate E2 partners, thereby preventing ubiquitin transfer to substrates (Garcia-Barcena et al, 2020;Gunn et al, 2013). We stably expressed wild-type MGRN1, MGRN1 Mut1 , or MGRN1 Mut2 in Mgrn1 À/À ;Rnf157 À/À NIH/3T3 cells and measured the abundance of GLI1, post-ER SMO, and ciliary SMO (Figures 3F and 3G).…”